Depression is on the wiki’s outcome menu as a patient-important QoL outcome (the 2026-08-08 QoL-extension) and through its physiological intersection with physical health — depression predicts and worsens cardiovascular disease, and shares the HPA / inflammation / metabolic channels the wiki already tracks -> Stress Management and Cardiometabolic Health, Inflammation as a Modifiable Lever. So modifiable-exposure -> depression is a legitimate appraisal claim. But it is held peripherally and proportionately: physical health is the focus, and this page is one nucleus over two levers, not a mental-health sub-domain.
The drug facet lives on its own page. The realistic alternative to these lifestyle levers — the antidepressant class, appraised as a standing drug for its efficacy and its limitations — is Antidepressants for Depression. Its class-vs-placebo estimates (OR/SMD) are on a different reference group than the exercise network’s SSRI-vs-active-control estimate below, so the two are not welded into a single head-to-head; the comparison and its caveats stay explicit at each point of use.
The binding caveat, up front — both levers rest on a SELF-REPORTED symptom-scale surrogate, and both literatures carry heterogeneity and publication bias. Depression symptom scales (BDI, CES-D, HDRS) are not the patient-important outcome of a diagnosed depressive disorder — they are a surrogate measured with error, and the certainty here is low. The direction (both levers help, or at least track lower depression) is more secure than the magnitude.
The two levers, ranked by warrant
— the ranking below is the wiki’s own synthesis across the two sources, not a claim in either.
| Lever | Best estimate | Design | Certainty | Direction secure? |
|---|---|---|---|---|
| Exercise (treatment of MDD) | g −0.4 to −0.6 vs active control | NMA of 218 RCTs | low / very low | yes |
| Diet quality (incidence of symptoms) | OR ~0.77 highest-vs-lowest | dose-response MA of prospective cohorts | low | contested (see diet section) |
Exercise is the better-warranted lever: it is randomised evidence on treating established depression, and the effect is not modified by baseline severity or comorbidity (equally effective across both — a subgroup finding, not a covariate adjustment). Diet quality is observational evidence on incidence, and its signal is fragile to the two checks that separate association from cause (below). Neither is a big rock on the physical-health axis — they enter the Layer-1 ranking as real but modest, low-certainty levers, and attention is an anti-signal here (nutritional psychiatry is heavily discussed and thinly evidenced).
Update — the diet lever now has a small treatment arm too. The ranking above places diet as observational-on-incidence only; that was the state before the SMILES trial. SMILES adds one small, unblinded RCT of dietary improvement as adjunctive treatment of existing major depression (below, Lever 2). It does not change the ranking — exercise stays the better-warranted lever (218 RCTs vs one n=67 trial) — but it means diet is no longer purely observational: there is now a randomised treatment signal, distinct in question from Molendijk’s prevention signal (the two are NOT the same claim — see the distinction below).
Lever 1 — Exercise treats depression (RCT-grade, low certainty)
A Bayesian network meta-analysis of 218 RCTs / 495 arms / 14,170 participants with major depressive disorder (Noetel 2024). Effects are improvement beyond active control (usual care, placebo tablet, stretching, education, social support), in Hedges’ g (negative = greater symptom reduction; MCID vs active control = g −0.20):
| Modality | g (95% CrI) | κ | Note |
|---|---|---|---|
| Dance | «−0.96 (−1.36 to −0.56)» | 5 | large but sparse; mostly young women — not strongly recommended |
| Walking / jogging | «−0.63 (−0.80 to −0.46)» | 51 | — |
| Yoga | «−0.55 (−0.73 to −0.36)» | 33 | — |
| Exercise + SSRI | «−0.55 (−0.86 to −0.23)» | 11 | adjuvant to drug |
| Strength training | «−0.49 (−0.69 to −0.29)» | 22 | — |
| Mixed aerobic | «−0.43 (−0.61 to −0.25)» | 51 | — |
| Tai chi / qigong | «−0.42 (−0.65 to −0.21)» | 12 | — |
| (comparator) CBT | «−0.55 (−0.75 to −0.37)» | 20 | — |
| (comparator) SSRI | «−0.26 (−0.50 to −0.01)» | 16 | — |
The strongest exercise modalities are comparable to CBT and larger than SSRIs alone within this network — though the review «was not designed to find all studies of these treatments, so these estimates should not usurp» the psychotherapy/pharmacotherapy-focused reviews. This is the layer-3 substitution point: exercise is a viable alternative or adjuvant to first-line treatment, not merely a last resort.
Dose is about INTENSITY, not volume — and not energy expenditure. «The effects of exercise were proportional to the intensity prescribed»: light PA «still provided clinically meaningful effects (g=−0.58, −0.82 to −0.33)», but expected effects were «stronger for vigorous exercise (eg, running, interval training; g=−0.74, −1.10 to −0.38)». Crucially «This finding did not appear to be due to increased weekly energy expenditure» — the METs/min dose-response was «unclear». So more calories burned is not the mechanism; intensity is. Benefits were «equally effective for different weekly doses». This is a genuinely different dose-response object from the volume/METs curve on Physical Activity Dose and Mortality — the mortality lever is dosed in weekly minutes, the depression lever in intensity.
Acceptability: strength training «0.55 (0.31 to 0.99)» and yoga «0.57 (0.35 to 0.94)» had lower dropout odds than active control — the two best-tolerated modalities, which matters because adherence is part of the effect (layer 3).
Effect is broad across strata: «Exercise appeared equally effective for people with and without comorbidities and with different baseline levels of depression.» Modality preference is modified by age/sex (strength for younger women, yoga for older men) — but these are study-level, confounded moderators («both sex and intervention may have changed»), a route-(b) effect-modification claim the data cannot actually support at the individual level.
Certainty is LOW / VERY LOW. «confidence in accordance with CINeMA was low for walking or jogging and very low for other treatments.» The dominant reason is within-study bias: blinding was rare, so «effect sizes could include expectancy effects» — the expectancy problem is acute for a self-reported outcome in an unblindable intervention. Publication bias was detected (Egger P<0.001, funnel asymmetry) but was not large enough to nullify the effect: «studies with statistically significant results would need to be reported 58 times more frequently» to erase it. Grey literature was not systematically searched.
Mechanism is unresolved: «Our review did not uncover clear causal mechanisms, but the trends in the data are useful for generating hypotheses.» The authors hypothesise a combination (social interaction, mindfulness/acceptance, self-efficacy, green space, neurobiology, acute positive affect) — no single modality covers all, and the mediation studies were underpowered. That the effect scales with intensity but not energy expenditure is itself a hint the pathway is neuro-affective, not metabolic.
Lever 2 — Diet quality tracks lower depression incidence (observational, and fragile)
A dose-response meta-analysis of prospective cohorts only — 29 articles / 24 cohorts / «1,959,217
person-years» (Molendijk 2017). This is a different exposure and a different question from the exercise
lever: diet quality (not a single nutrient) and incidence of depression (not treatment). It is
NOT type-E corroboration of the exercise finding — different exposure, different author group, different
design — so no [E-independent] tag joins them; they are two distinct levers on one outcome.
Higher-quality diet -> lower incident depression, highest vs lowest adherence (OR):
| Exposure | OR (95% CI) | Dose-response? |
|---|---|---|
| Healthy diet (overall) | «0.77 (0.69 to 0.84)» | linear, P<0.01 |
| Mediterranean | «0.75 (0.67 to 0.84)» | (part of the linear overall) |
| Dietary inflammatory index (low vs high) | «0.81 (0.71 to 0.92)» | no |
| Fish | «0.86 (0.78 to 0.95)» | no |
| Vegetables | «0.82 (0.70 to 0.97)» | no |
| Low-quality diet | «1.03» to «1.11» (all NS) | no |
The asymmetry is a finding: a protective signal for high-quality diets, but «Adherence to low quality diets and food groups was not associated with higher depression incidence». If poor diet caused depression you would expect the harmful arm to appear; it does not.
The two vanishing-tests — why this lever’s causal reading is contested. The association survives only in the softest analyses, and dies under the two checks that separate cause from artifact:
- Adjusting for baseline (subclinical) depressive symptoms collapses the effect: OR «0.72 (0.65 to 0.79)» -> «0.96 (0.87 to 1.06)». The authors read this as possible reverse causation — a poor diet «may be a concomitant phenomenon of the early stage of depression without being genuinely associated to depression risk» — while noting the counter-possibility of over-correction (diet is a lifelong habit).
- Using a formal DIAGNOSIS as the outcome (rather than a symptom scale) also nulls it: OR «0.91 (0.68 to 1.23)» vs symptom-scale «0.72 (0.65 to 0.81)». Metabolic disease shares somatic symptoms (fatigue, weight change) with depression, so a symptom scale can register diet’s metabolic effect as if it were depression — a surrogate-inflation mechanism, not a mood effect.
Together these are the artifact-first discipline applied to a protective arm: the signal is «less than unequivocal» exactly where the measurement is hardest, and the authors themselves conclude «the claim that a low-quality diet is a central determinant of depression risk is, given the current data, questionable».
Magnitude framing, honestly hedged. NNB «47 (34 to 80)» to move one person from lowest to highest diet quality to prevent one case — which the authors say «compares favourably to the NNB for widely prescribed medications such as statins in the primary prevention of cardiac disease», with high-quality food carrying «no risk, only gain». Read this as an upper-bound framing: it inherits the reverse- causation fragility above and the dietary measurement error that biases the NNB.
Mechanism points back at the cardiometabolic pathway: the favoured route is «certain dietary habits may predispose to metabolic illness, which in turn poses risk for depression» — i.e. the diet-depression link may be partly mediated by the cardiometabolic big rocks the wiki already tracks, not an independent lever. The dietary inflammatory index signal (OR 0.81) is the low-heterogeneity edge of this -> Inflammation as a Modifiable Lever. No RCT prevention trial exists («To date, no such a trial has been performed») — the whole lever rests on observational prospective data.
The SMILES trial — diet as adjunctive TREATMENT (one small unblinded RCT)
The AWAITS above has landed. SMILES (Jacka 2017) is «the first RCT to explicitly seek to answer the question: If I improve my diet, will my mental health improve?». Design: «a 12-week, parallel-group, single blind, randomised controlled trial of an adjunctive dietary intervention in the treatment of moderate to severe depression» — seven dietician-led sessions promoting a Mediterranean-style diet versus a social-support (befriending) control, in adults already in treatment for MDD. It «randomised 67 individuals with MDD to the trial (intervention, n = 33; social support control, n = 34)». Primary outcome: MADRS at 12 weeks.
Result: «The dietary support group demonstrated significantly greater improvement in MADRS scores between baseline and 12 weeks than the social support control group, t(60.7) = 4.38, p < .001». Effect size «Cohen’s d of -1.16 (95% CI -1.73, -0.59)», an «average between group difference … of 7.1 points on the MADRS». Remission: «32.3% (n = 10) of the dietary support group and 8.0% (n = 2) of the social support control group achieved remission criteria of a score less than 10 on the MADRS», between-group «χ2 (1) = 4.84, p = 0.028», NNT «4.1 (95% CI of NNT 2.3-27.8)».
Do not over-read this — n=67, single unblinded trial, tiny-n (registry tier = moderate). The authors name the binding threat themselves: «there is the issue of expectation bias due to the fact that we needed to be explicit in our advertising regarding the nature of the intervention and to the inability to blind the participants to their intervention group; this may have biased the results and also resulted in differential dropout rates» (completion 94% diet vs 73.5% control), and failure to reach the planned sample «may also have inflated the effect size we observed». Under a not-missing-at-random sensitivity model «observed intervention effects moved towards the null» (though «robust against departures from the MAR assumption»). Evidence state = insufficient / promising, NOT established: one small unblinded RCT that replaces reverse causation (via randomisation) with expectancy bias (via no blinding). A large Cohen’s d is exactly what unblinding + tiny-n + differential dropout would manufacture, so the number does not settle causation.
Treatment (SMILES) vs prevention (Molendijk) — a DISTINCTION, not a tension, not corroboration
The two diet findings answer DIFFERENT questions and must not be pooled, filed as a [[tension]], or read
as type-E independent backing. Not-joined check (ii) fires — different population, outcome, and horizon:
| Parameter | SMILES (Jacka 2017) | Molendijk 2017 | Same quantity? |
|---|---|---|---|
| Design | single-blind RCT (n=67) | dose-response MA of prospective cohorts | NO |
| Population | adults WITH existing MDD | non-depressed at baseline | NO |
| Exposure | 12-wk dietician-led diet change | habitual diet quality, highest vs lowest | NO |
| Outcome | MADRS symptom change (treat) | INCIDENCE of depression (prevent) | NO |
| Estimand | between-group change in symptoms | OR of becoming an incident case | NO |
| Effect | d -1.16; 7.1 MADRS points | OR 0.77 highest-vs-lowest | NO — treat vs prevent |
Every row is NO: a treatment effect on symptom trajectory in the already-ill is a different object from a prevention association on incidence in the well. Filing this as a tension would be a fake tension; scoring it as type-E would launder two non-same, non-independent claims into false robustness. It is a distinction — the two levers bracket the diet-depression question at opposite ends (prevent vs treat) without either establishing the causal link.
The beyond-summary composite (type-F refinement). Molendijk’s prevention signal is fragile precisely to reverse causation — adjusting for baseline symptoms collapses it (OR 0.72 -> 0.96 above). SMILES randomises the diet change, which is the one manoeuvre an observational cohort cannot perform, so it removes reverse causation as the explanation for its result. But it does not thereby inherit clean causal status: unblinding substitutes expectancy bias for reverse causation. So the composite that neither source states alone is — randomisation answers Molendijk’s fatal confounder but opens a new one, and neither design alone (nor the two stacked) establishes that improving diet lifts depression. The honest net reading: diet is a candidate causal lever carrying a small randomised treatment signal plus a fragile observational prevention signal, still short of established.
G-gap (unheld future source): no powered, adequately-blinded-or-active-control-matched replication RCT of dietary improvement as depression treatment yet exists; that is what would move this lever from insufficient/promising toward established, and would count as type-E corroboration only if its independent design also rules out expectancy bias.
Synthesis — what this domain does and does not license
- The expectancy trap is the load-bearing limit. An unblindable behaviour (exercise, diet) measured by
a self-reported symptom scale is the worst case for expectancy bias, and it is exactly the setup here.
That is why direction is held more firmly than magnitude, and why the whole page sits at
confidence: lowdespite one lever being RCT-based. - Decision-change (layer 3): for a person with depression who is willing, exercise — favouring intensity they can sustain, in a structured prescription, with strength or yoga if tolerability is the binding constraint — is a defensible alternative or adjuvant to psychotherapy/pharmacotherapy, not merely a fallback. The wiki appraises; it does not prescribe, screen, or manage the disorder (the prescriber/acute-care line).
- Diet as adjunct is now a candidate, not a fallback — but weakly. SMILES adds a single small unblinded RCT showing diet improvement can treat symptoms (not just track lower incidence), so dietician-supported dietary improvement is a reasonable low-risk adjunct to consider — while holding that one n=67 expectancy-prone trial is insufficient to establish the effect, and that the prevention and treatment claims are a distinction, not one finding.
- Open loop: no operation here grades these against a realized patient outcome; the evidence is symptom-scale change, and the trajectory/quality-of-life shape depression most degrades is under-measured.